Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Peterson

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMC Health Services Research|August 31, 2021
Health and resource burden of a cancer diagnosis on the caregiver: an analysis of administrative claims dataLisa M Hess, Siew Hoong Wong-Jacobson, Patrick M Peterson
Acta Oto-Laryngologica|January 8, 2020
Robustness of an Adaptive Beamforming Method for Hearing AidsPatrick M Peterson, Su-Min Wei, William M Rabinowitz, et al.
The Oncologist|October 29, 2024
Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeLuis E Raez, Ashish C Massey, Scott S Barker, et al.
Cancers|November 27, 2024
Real-World Outcomes of Selective <i>RET</i> Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two DatabasesChi-Yin Liao, Carmen Gonzalez-Ferrer, Samuel Whipple, et al.
Future Oncology (London, England)|April 19, 2021
Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> exon 19 deletions or exon 21 mutationsKatherine B Winfree, Cliff Molife, Patrick M Peterson, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2018
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcomaRobin L Jones, Gary Mo, John R Baldwin, et al.
Cancers|December 23, 2022
<i>TP53</i> Co-Mutation Status Association with Clinical Outcomes in Patients with <i>EGFR</i>-Mutant Non-Small Cell Lung CancerXiuning Le, Cliff Molife, Mark S Leusch, et al.
Cancers|October 14, 2023
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue SarcomasSteven Attia, Victor Villalobos, Nadia Hindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized TrialRobin L Jones, Andrew J Wagner, Akira Kawai, et al.
Journal of Gastric Cancer|May 2, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Health Services Research|August 31, 2021
Health and resource burden of a cancer diagnosis on the caregiver: an analysis of administrative claims dataLisa M Hess, Siew Hoong Wong-Jacobson, Patrick M Peterson
Acta Oto-Laryngologica|January 8, 2020
Robustness of an Adaptive Beamforming Method for Hearing AidsPatrick M Peterson, Su-Min Wei, William M Rabinowitz, et al.
The Oncologist|October 29, 2024
Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeLuis E Raez, Ashish C Massey, Scott S Barker, et al.
Cancers|November 27, 2024
Real-World Outcomes of Selective <i>RET</i> Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two DatabasesChi-Yin Liao, Carmen Gonzalez-Ferrer, Samuel Whipple, et al.
Future Oncology (London, England)|April 19, 2021
Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> exon 19 deletions or exon 21 mutationsKatherine B Winfree, Cliff Molife, Patrick M Peterson, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2018
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcomaRobin L Jones, Gary Mo, John R Baldwin, et al.
Cancers|December 23, 2022
<i>TP53</i> Co-Mutation Status Association with Clinical Outcomes in Patients with <i>EGFR</i>-Mutant Non-Small Cell Lung CancerXiuning Le, Cliff Molife, Mark S Leusch, et al.
Cancers|October 14, 2023
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue SarcomasSteven Attia, Victor Villalobos, Nadia Hindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized TrialRobin L Jones, Andrew J Wagner, Akira Kawai, et al.
Journal of Gastric Cancer|May 2, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.
Pageof 2